Moreover, CDK2 was identified as a synthetic lethality partner of N-MYC in neuroblastoma cells, as therapeutically feasible doses of roscovitine, a CDK inhibitor, caused N-MYC-dependent cell death, supporting the notion of synthetic lethality between the two proteins [52]. This evidence concerns the gene MYCN and neuroblastoma.